RxDoctor Payments Data

Katherine Koonce

Family · Fort Worth, TXNPI 1760012256

Payments from drug & device makers

$7,641in general payments, 2019–2025

Across 372 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$969
  • AbbVie$953
  • AstraZeneca$922
  • Novo Nordisk$922
  • Lilly USA, LLC$795
  • Boehringer Ingelheim$444
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,47398%
  • Education$1682%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,641 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$57,952
Medicare patients
199
Services billed
754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$119,502
JardianceEmpagliflozin35$42,425
EliquisApixaban40$40,067
XareltoRivaroxaban22$22,954
JanuviaSitagliptin Phosphate19$22,933
FarxigaDapagliflozin Propanediol20$15,370
TradjentaLinagliptin16$14,273
LinzessLinaclotide20$13,215
MounjaroTirzepatide11$9,097
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$9,090
SymbicortBudesonide/Formoterol Fumarate13$5,164
Rosuvastatin Calcium262$3,581
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,549
Levothyroxine Sodium237$2,700
Gabapentin120$2,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$922$119,502109 claims
Boehringer IngelheimJardiance, Tradjenta$444$56,69851 claims
PfizerEliquis$324$40,06740 claims
Johnson & JohnsonXarelto$33$22,95422 claims
MerckJanuvia$101$22,93319 claims
AstraZenecaFarxiga, Symbicort$922$20,53533 claims
AbbVieLinzess, Synthroid$953$15,37746 claims
Lilly USA, LLCMounjaro$795$9,09711 claims
Sanofi-aventis U.S. LLCLantus$164$1,61719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →